Is Globus Medical (GMED) overvalued? · P/E 42, rev $1.55B
Globus Medical (GMED) is a medical devices company listed on US.
This page asks whether Globus Medical (GMED) looks expensive on cached numbers — not a short thesis.
Latest reported GMED revenue for 2026-06-30 was $1.55B. Net income was $275.9M. GMED currently screens at market cap $7.66B and trailing P/E 42.1.
GMED currently screens at market cap $7.66B and trailing P/E 42.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GMED 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GMED stock page for the full model, not this heading.
Not investment advice.